Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 291 to 300 of 1090 total matches.
Roflumilast Foam (Zoryve) for Seborrheic Dermatitis
The Medical Letter on Drugs and Therapeutics • Apr 15, 2024 (Issue 1700)
area of skin
and for the shortest duration possible.
DRUG INTERACTIONS — Roflumilast is a substrate ...
The FDA has approved a 0.3% foam formulation of
the phosphodiesterase-4 (PDE4) inhibitor roflumilast
(Zoryve – Arcutis) for topical treatment of seborrheic
dermatitis in patients ≥9 years old. Roflumilast is
the first PDE4 inhibitor to be approved in the US for
this indication. It is also available in a 0.3% cream
formulation (Zoryve) for treatment of plaque psoriasis
and in an oral formulation (Daliresp, and generics) for
treatment of chronic obstructive pulmonary disease.
A 0.15% cream formulation for treatment of atopic
dermatitis in patients ≥6 years old will be reviewed...
Med Lett Drugs Ther. 2024 Apr 15;66(1700):57-9 doi:10.58347/tml.2024.1700a | Show Introduction Hide Introduction
Letermovir (Prevymis) for CMV Prophylaxis
The Medical Letter on Drugs and Therapeutics • Dec 16, 2019 (Issue 1587)
has not been
associated with myelotoxicity or nephrotoxicity.
▶ Many potentially troublesome drug interactions.
CMV ...
The FDA has approved letermovir (Prevymis – Merck),
a cytomegalovirus (CMV) DNA terminase complex
inhibitor, for prophylaxis of CMV infection and disease
in CMV-seropositive adult recipients of an allogeneic
hematopoietic cell transplant (HCT). Letermovir is
the first CMV DNA terminase complex inhibitor to
be approved in the US and the only drug specifically
indicated for CMV prophylaxis in HCT patients. It is not
approved for treatment of CMV infection.
A Once-Daily Combination Tablet (Atripla) for HIV
The Medical Letter on Drugs and Therapeutics • Sep 25, 2006 (Issue 1244)
other
than stavudine and zidovudine.
DRUG INTERACTIONS — Efavirenz is metabolized
by, and can both induce ...
Atripla (Gilead/Bristol-Myers Squibb) is the first once daily, single-tablet combination of 3 antiretroviral drugs for treatment of HIV infection. Each tablet contains 600 mg of the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (Sustiva), 200 mg of the nucleoside reverse transcriptase inhibitor (NRTI) emtricitabine (Emtriva), and 300 mg of the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir DF (Viread). These drugs have been recommended for use together, if resistance testing confirms susceptibility, as an initial regimen of choice for treatment-na∩ve...
Topical Roflumilast (Zoryve) for Plaque Psoriasis
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023 (Issue 1668)
to severe
hepatic impairment (Child-Pugh B or C).
Drug Interactions: May interact with CYP3A4 inhibitors ...
The FDA has approved a 0.3% cream formulation of
the phosphodiesterase-4 (PDE4) inhibitor roflumilast
(Zoryve – Arcutis) for topical treatment of plaque
psoriasis in patients ≥12 years old. Roflumilast is
the first topical PDE4 inhibitor to be approved by the
FDA for this indication; crisaborole (Eucrisa), another
topical PDE4 inhibitor, is approved for treatment
of atopic dermatitis. Oral roflumilast (Daliresp)
is approved for treatment of chronic obstructive
pulmonary disease.
Med Lett Drugs Ther. 2023 Jan 23;65(1668):10-2 doi:10.58347/tml.2023.1668b | Show Introduction Hide Introduction
Safinamide (Xadago) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Sep 11, 2017 (Issue 1529)
; no data on the presence of
safinamide in human breast milk are available.
DRUG INTERACTIONS — Use ...
The FDA has approved the monoamine oxidase
type B (MAO-B) inhibitor safinamide (Xadago – US
Worldmeds) as an adjunct to levodopa/carbidopa
for management of "off" episodes in patients with
Parkinson’s disease (PD). It is the first reversible
MAO-B inhibitor to be approved for this indication.
Selegiline (Eldepryl, and others) and rasagiline
(Azilect, and generics), two irreversible MAO-B
inhibitors, have been used alone and as adjuncts to
levodopa/carbidopa for many years. Safinamide is
not approved for use as monotherapy.
Rifaximin (Xifaxan) for Travelers' Diarrhea
The Medical Letter on Drugs and Therapeutics • Sep 13, 2004 (Issue 1191)
oral dose
adjusted for body surface area.
DRUG INTERACTIONS — Rifaximin can induce
CYP3A4 ...
Rifaximin (Xifaxan - Salix), a non-absorbed oral antibiotic derived from rifampin (Rifadin, and others), has been approved by the FDA for treatment of travelers' diarrhea caused by noninvasive strains of Escherichia coli in patients 12 years of age or older. It has been available in Europe since 1987.
Meloxicam (Mobic) for Osteoarthritis
The Medical Letter on Drugs and Therapeutics • May 29, 2000 (Issue 1079)
Rheumatol, 35 Suppl 1:22, 1996).
DRUG INTERACTIONS — Pretreatment with cholestyramine (Questran, and others ...
Meloxicam, a nonsteroidal anti-inflammatory drug (NSAID) with some cyclooxygenase-2 (COX-2) selectivity in vitro, has been approved by the FDA for treatment of osteoarthritis.
Dofetilide for Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • May 15, 2000 (Issue 1078)
, the incidence was
3.3% and two of these patients died.
DRUG INTERACTIONS — Drugs that interfere with cation ...
Dofetilide (Tikosyn - Pfizer), a new methanesulfonamide antiarrhythmic drug, has recently been marketed for oral treatment of atrial fibrillation and flutter.
A Diclofenac Patch (Flector) for Pain
The Medical Letter on Drugs and Therapeutics • Jan 14, 2008 (Issue 1277)
. Schwartz, M.D., Mount Sinai School of Medicine
DRUG INTERACTIONS FELLOW: Emily Ung, BScPhm, Children’s ...
Diclofenac epolamine patch 1.3% (Flector Patch - Alpharma), a topical formulation of the nonsteroidal anti-inflammatory drug (NSAID) diclofenac, has been approved by the FDA for topical treatment of acute pain due to minor strains, sprains and contusions. It is the first topical NSAID patch approved in the US. A diclofenac patch has been used in Europe since 1993. Diclofenac sodium (Voltaren, and others) is available in the US as an oral tablet, in a 1% gel for treatment of osteoarthritis (to be reviewed in a future issue), in a 3% gel (Solaraze) for treatment of actinic keratoses, and in an...
Mometasone/Formoterol (Dulera) for Asthma
The Medical Letter on Drugs and Therapeutics • Oct 18, 2010 (Issue 1349)
for use in pregnancy (risk cannot be ruled out).
DRUG INTERACTIONS — Systemically absorbed formoterol ...
A combination of the corticosteroid mometasone furoate (Asmanex) and the long-acting beta2-agonist
(LABA) formoterol (Foradil) has become available in a
single metered-dose inhaler (Dulera – Schering) for
treatment of asthma in patients ≥12 years old. It is the
third corticosteroid/LABA combination inhaler to
become available for this indication in the US. None of
these combinations should be used for initial treatment
of asthma or for acute treatment of asthma symptoms.